More recent studies have confirmed the importance of this interaction, showing that specific tTG inhibitors such as KCC009 can block α-synuclein aggregation in SH-SY5Y neuroblastoma cells [51], and that tTG and α-synuclein both localize to the endoplasmic reticulum in disease brain samples [49]. This evidence concerns the gene TGM2 and neuroblastoma.